Competitive LandscapeApril 2026
Roche's Fenebrutinib Achieves Positive Phase III Results in MS — First BTK Inhibitor Targeting Both B Cells and Microglia
Fenebrutinib (Roche/Genentech) becomes the first BTK inhibitor with positive Phase III results in both relapsing AND primary progressive MS. FENhance 2 showed 59% relapse rate reduction vs teriflunomide; FENtrepid demonstrated non-inferiority vs ocrelizumab in PPMS.
JFInnova Perspective
Fenebrutinib validates the dual hypothesis (B cells + microglia) that JFIN-0001 pursues. However, fenebrutinib is an oral small molecule with systemic effects on all BTK-expressing cells. JFIN-0001 offers surgical specificity: it exclusively blocks MIF/CD74, without the hepatic and hematological off-target effects of BTK inhibitors.
References
1
Genentech's Fenebrutinib Shows Unprecedented Positive Phase III Results in Both Relapsing and Primary Progressive MS
Genentech Press Release · 2025
2
Fenebrutinib Confirms Its Potential in Third Positive Phase III Study (FENhance 1)
Genentech Press Release · 2026
Fenebrutinib BTK MS microglia B cells